Global Cord Blood Corporation (CO)
ValueMarkers Composite Index
DCF data not available
Global Cord Blood Corporation (CO) — VMCI valuation read
Global Cord Blood Corporation (CO) carries a VMCI composite of 70/100, 20 points above the Healthcare sector median of 50. Among mid-cap names, that gap places CO in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).
The CO insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.
**Investor frame.** Value reads CO trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -1.5x leaves covenant headroom, the line to track on Global Cord Blood Corporation's next 10-Q.
CO rose 3.6% over the trailing 7 days, with a +8.0% read on a 30-day basis.
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.